Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1344-1358

  Jeffrey, Scott C ^a   Torgov, Michael Y ^a   Andreyka, Jamie B ^a   Boddington, Laura ^a   Cerveny, Charles G ^a   Denny, William A ^b   Gordon, Kristine A ^a   Gustin, Darin ^a   Haugen, Jennifer ^a   Kline, Toni ^a   Nguyen, Ï Minh T ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 AMINO 1 CHLOROMETHYL 1,2 DIHYDROBENZO[3]INDOL 3 YL) 3 (4 METHOXYPHENYL)PROPENONE; 4 AMINOBENZYL CARBAMATE; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CARBAMIC ACID DERIVATIVE; CATHEPSIN B; CITRULLINE; DIPEPTIDE; DNA MINOR GROOVE BINDER; ETHYLENE GLYCOL DERIVATIVE; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F6; MONOCLONAL ANTIBODY CAC10; MONOCLONAL ANTIBODY CBR96; MONOMER; TETRAETHYLENEGLYCOL; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; ARTICLE; CELL KILLING; CELL LINE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; LYSOSOME; REACTION ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; AZA COMPOUNDS; CATHEPSIN B; CELL LINE, TUMOR; CYCLOPROPANES; DIPEPTIDES; DNA; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; INDOLES; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144367846     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040137q     Document Type: Article

References (39)

1. Dubowchik, G. M.; Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 1999, 83, 67-123.
2. Meyer, D. L.; Senter, P. D. Recent advances in antibody drug conjugates for cancer therapy. Annu. Rep. Med. Chem. 2003, 38, 229-237.
3. Damle, N. K.; Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharmacol. 2003, 3, 386-390.
4. Giles, F.; Estey, E.; O'Brien, S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003, 98, 2095-2104.
5. Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261, 212-215.
6. Saleh, M. N.; Sugarman, S.; Murray, J.; Ostroff, J. B.; Healey, D.; Jones, D.; Daniel, C. R.; LeBherz, D.; Brewer, H.; Onetto, N.; LoBuglio, A. F. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 2000, 18, 2282-2292.
7. Liu, C.; Tadayoni, B. M.; Bourret, L. A.; Mattocks, K. M.; Derr, S. M.; Widdison, W. C.; Kedersha, N. L.; Ariniello, P. D.; Goldmacher, V. S.; Lambert, J. M.; Blattler, W. A.; Chari, R. V. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8618-8623.
8. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C. P.; Xie, H.; Wilhelm, S. D.; Leece, B. A.; Bartle, L. M.; Goldmacher, V. S.; Chari, R. V. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620-5623.
9. Chari, R. V.; Jackel, K. A.; Bourret, L. A.; Derr, S. M.; Tadayoni, B. M.; Mattocks, K. M.; Shah, S. A.; Liu, C.; Blattler, W. A.; Goldmacher, V. S. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995, 55, 4079-4084.
10. Suzawa, T.; Nagamura, S.; Saito, H.; Ohta, S.; Hanai, N.; Kanazawa, J.; Okabe, M.; Yamasaki, M. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Controlled Release 2002, 79, 229-242.
11. Suzawa, T.; Nagamura, S.; Saito, H.; Ohta, S.; Hanai, N.; Yamasaki, M. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly-(ethylene glycol)-dipeptidyl linker capable of tumor specific activation. Bioorg. Med. Chem. 2000, 8, 2175-2184.
12. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778-784.
13. Francisco, J. A.; Cerveny, C. G.; Meyer, D. L.; Mixan, B. J.; Klussman, K.; Chace, D. F.; Rejniak, S. X.; Gordon, K. A.; DeBlanc, R.; Toki, B. E.; Law, C. L.; Doronina, S. O.; Siegall, C. B.; Senter, P. D.; Wahl, A. F. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458-1465.
14. Boger, D. L.; Johnson, D. S. CC-1065 and the duocarmycins: Unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649.
15. Yasuzawa, T.; Muroi, K.; Ichimura, M.; Takahashi, I.; Ogawa, T.; Takahashi, K.; Sano, H.; Saitoh, Y. Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp. structures and chemistry. Chem. Pharm. Bull. 1995, 43, 378-391.
16. Atwell, G. J.; Wilson, W. R.; Denny, W. A. Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI. Bioorg. Med. Chem. Lett. 1997, 7, 1489-1594.
17. Atwell, G. J.; Milbank, J. J.; Wilson, W. R.; Hogg, A.; Denny, W. A. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: Relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. J. Med. Chem. 1999, 42, 3400-3411.
18. Denny, W. A.; Wilson, W. R.; Ware, D. C.; Atwell, G. J.; Milbank, J. B.; Stevenson, R. J. Anti-Cancer 2,3-Dihydro-1H-pyrroloc[3,2-f]quinoline Complexes of Cobalt and Chromium; New Zealand, 2002; p 92.
19. Xie, H.; Audette, C.; Hoffee, M.; Lambert, J. M.; Blattler, W. A. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 2004, 308, 1073-1082.
20. Tietze, L. F.; Lieb, M.; Herzig, T.; Haunert, F.; Schuberth, I. A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs. Bioorg. Med. Chem. 2001, 9, 1929-1939.
21. Hay, M. P.; Anderson, R. F.; Ferry, D. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J. Med. Chem. 2003, 46, 5533-5545.
22. King, H. D.; Dubowchik, G. M.; Mastalerz, H.; Willner, D.; Hofstead, S. J.; Firestone, R. A.; Lasch, S. J.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 2002, 45, 4336-4343.
23. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J.; Mosure, K.; Knipe, J. O.; Lasch, S. J.; Trail, P. A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 2002, 13, 855-869.
24. Walker, M. A.; Dubowchik, G. M.; Hofstead, S. J.; Trail, P. A.; Firestone, R. A. Synthesis of an immunoconjugate of camptothecin. Bioorg. Med. Chem. Lett. 2002, 12, 217-219.
25. Toki, B. E.; Cerveny, C. G.; Wahl, A. F.; Senter, P. D. Protease-mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer prodrugs. J. Org. Chem. 2002, 67, 1866-1872.
26. Denny, W. A. DNA minor groove alkylating agents. Curr. Med. Chem. 2001, 8, 533-544.
27. Yang, S.; Denny, W. A. A new short synthesis of 3-substituted 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles (amino-CBIs). J. Org. Chem. 2002, 67, 8958-8961.
28. Honda, M.; Morita, H.; Nagakura, I. Deprotection of allyl groups with sulfinic acids and palladium catalyst. J. Org. Chem. 1997, 62, 8932-8936.
29. Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
30. Carpino, L. A.; El-Faham, A. Effect of tertiary bases on O-benzotriazolyluronium salt-induced peptide segment coupling. J. Org. Chem. 1994, 59, 695-698.
31. Belleau, B.; Malek, G. New convenient reagent for peptide syntheses. J. Am. Chem. Soc. 1968, 90, 1651-1652.
32. Corey, E. J.; Venkateswarlu, A. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.
33. Zeng, Z.; Zimmerman, S. C. Convenient synthesis of 9-alkyl and 9-arylacridines from [2-(trimethylsilyl) ethoxy] methyl (sem) protected acridone. Tetrahedron Lett. 1988, 29, 5123-5124.
34. Wahl, A. F.; Klussman, K.; Thompson, J. D.; Chen, J. H.; Francisco, L. V.; Risdon, G.; Chace, D. F.; Siegall, C. B.; Francisco, J. A. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002, 62, 3736-3742.
35. Hishima, T.; Fukayama, M.; Hayashi, Y.; Fujii, T.; Ooba, T.; Funata, N.; Koike, M. CD70 expression in thymic carcinoma. Am. J. Surg. Pathol. 2000, 24, 742-746.
36. Held-Feindt, J.; Mentlein, R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int. J. Cancer 2002, 98, 352-356.
37. Reeve, J. G.; Rabbitts, P. H.; Twentyman, P. R. Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br. J. Cancer 1989, 60, 339-342.
38. Walter, R. B.; Raden, B. W.; Hong, T. C.; Flowers, D. A.; Bernstein, I. D.; Linenberger, M. L. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003, 102, 1466-1473.
39. Bajkowski, A. S.; Frankfater, A. Specific spectrophotometric assays for cathepsin B1. Anal. Biochem. 1975, 68, 119-127.